Robert A. Bohrer
Professor of Law
LL.M. Harvard University
J.D. University of Illinois
B.A. Haverford College [psychology]
Courses Taught: Biotechnology Seminar,
Food and Drug Law, Torts II
Professor Bohrer practiced with the Chicago law firm of Bell, Boyd & Lloyd before returning to academia. Although he has written about such varied topics as the constitutionality of I.Q. testing in the public schools, congressional control of affirmative action, and the risks of toxic substances, since 1984 he has focused primarily on the legal issues raised by developments in biotechnology and pharmaceutical policy.
Professor Bohrer is a member of the executive board of the Biolaw Section of the AALS and previously served on the Council of the ABA Section of Science and Technology. Bohrer was executive editor of Biotechnology Law Report from 1999 to 2011. He previously served as director of Biotechnology Programs at the University of California at San Diego's Center for Molecular Genetics and and on the board of directors of the La Jolla Institute for Molecular Medicine. Bohrer was the only law professor to serve on the board of directors of the Biotechnology Institute of the U.S. Patent and Trademark Office. While in law school at Illinois, he was a member of Law Review and a teaching assistant in the College of Commerce.
- "Reach-Through Claims For Drug Target Patents: Rx For Pharmaceutical Policy," 26 Nature Biotechnology 55 (January 2008).
- A GUIDE TO BIOTECHNOLOGY LAW AND BUSINESS (2007).
- "It's the Antigen Stupid: A Risk/Reward Approach to the Problem of Orphan Drug Act Exclusivity for Monoclonal Antibody Therapeutics," 5 Columbia Science & Technology Law Review 1 (2003).
- "Eschazabal, Genetic Testing and Rawls: The Ethics of Protecting Workers Against Risks," in Biotechnology Law 2002: Biotechnology Patents & Business Strategies (Berholtz & Ludwig, eds., 2002).
- "A Rawlsian Approach to Solving the Problem of Genetic Discrimination in Toxic Workplaces," 39 San Diego Law Review 747 (2002).
- "The Trouble With Formularies: Where's the Data When You Need It?" Proceedings of the Fifth Annual Managed Care Law Summit (2002).
- "Letter: The Pharmaceutical Industry - to Whom is it Accountable?" 343 New England Journal of Medicine 1415 (2000).
- "Pharmaceutical Policy and Public Health: An Information Prescription for Pharmaceutical Policy," presented to the American Society for Law, Medicine & Ethics Health Law Professors Conference, Austin, TX, June 4, 2010.
- "The Reverse Doctrine of Equivalents to Limit Reach- Through Claims to Drug Target Patents," presented to The 2010 Intellectual Property Scholars Roundtable, Drake University Law School, Des Moines, IA, March 26, 2010.
- "Why is this drug different from all the other drugs? An agenda for law and pharmaceutical policy," presented to the Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, December 11th 2009.
"Ethical Issues: Longevity Research and Clinical Trials," Biotechnology Law 2005, Practicing Law Institute California Center, November 2005, San Francisco, CA.
"Recent Developments in Patent Law: What do they Mean for University Researchers?" Summer Neuropeptide Society Meeting, July 2005, Miami Beach, CA.
"Applying Ethical Reasoning in the Debate Over Social Policy: Embryonic Stem Cell Research," Lawyers' Club, March 2005, San Diego, CA.
225 Cedar Street
San Diego, CA 92101